Berlin, August 21, 2025 - YPOG advised an investor consortium led by Kurma Partnerson a EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.
With the new funding, EvlaBio will advance the development of its lead asset — a novel monoclonal antibody targeting the FGF23/FGFR4 signaling axis, a key driver of cardiac remodeling in patients with chronic kidney disease (CKD). The therapy is specifically aimed at treating left ventricular hypertrophy, a common and serious complication in CKD.
EvlaBio is a life science company focused on the development of first-in-class therapeutics for cardiovascular and cardiorenal diseases. Its lead program targets the FGFR4/FGF23 signaling axis, which is a key driver of cardiac remodeling in chronic kidney disease. By developing novel mechanisms based on sound science, EvlaBio aims to develop new treatment paradigms for CKD patients with high unmet medical needs.
About Kurma Partners
Kurma Partners is a key European player in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth stage. Based in Paris and Munich, it operates several specialized funds and collaborates closely with top research institutes.
About Boehringer Ingelheim Venture Fund (BIVF)
Founded in 2010, BIVF invests in groundbreaking biotech and digital health innovations. With a fund volume of 350 million EUR, it supports over 40 companies addressing major unmet medical needs.
About AdBio Partners
AdBio Partners is a Paris- and Barcelona-based VC focused on early-stage therapeutic-oriented projects. Since 2016, it has backed 28 European startups that have raised over one billion EUR in follow-on funding.
About High-Tech Gründerfonds (HTGF)
HTGF is one of Europe’s most active early-stage investors. Since 2005, it has financed over 780 startups and achieved nearly 200 exits. The fund has a volume of over two billion EUR.
About NRW.Venture (NRW.BANK)
NRW.Venture is the venture capital fund of NRW.BANK, investing up to 15 million EUR in innovative startups alongside private investors. Since 2005, it has supported over 30 life sciences companies.
Team
Dr. Martin Schaper (Transactions), Partner, Berlin
Jörg Schrade (Tax), Partner, Munich
Dr. Benedikt Flöter (IP/IT/Data Protection), Partner, Hamburg
Ciro D’Amelio (Transactions), Associate, Berlin
Christoph Cordes (IP/IT/Data Protection), Associate, Berlin
Boris Schinzel (Transactions), Associate, Berlin
Ninetta Kleindienst (Tax), Associate, Munich
Our colleagues from Walder Wyss supported the investor consortium on Swiss legal and tax aspects.
Kontakt
About us
YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 150 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Hamburg, Cologne, and Munich.
Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog